Drug intelligence / Profile preview

SD70

Development stage: Preclinical
Lead developer: National Institutes of Health
Modality: Small Molecules

Overview

SD70 is a **small molecule inhibitor** targeting KDM4C, a lysine demethylase enzyme implicated in epigenetic reprogramming critical for the maintenance of MLL-rearranged acute myeloid leukemia (AML). By inhibiting KDM4C, SD70 disrupts the leukemogenic program driven by MLL fusion proteins. It has demonstrated preclinical efficacy, especially when combined with other agents such as the menin inhibitor MI-503, resulting in synergistic induction of apoptosis in MLL::AF9-driven AML cells and prolonged survival in AML xenograft models[1].

Targets

KDM4C (Lysine-specific demethylase 4C)

Beyond the preview

Go deeper on SD70.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SD70.

Explore the full profile